Xeris Biopharma Holdings, Inc.
General ticker "XERS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Xeris Biopharma Holdings, Inc. follows the US Stock Market performance with the rate: 12.3%.
Estimated limits based on current volatility of 3.3%: low 8.28$, high 8.84$
Factors to consider:
- Total employees count: 651 (+65.2%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Economic downturns and volatility, Regulatory and compliance, Dilution from capital raising, Inability to achieve profitability, Market competition
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [6.41$, 12.25$]
- 2026-12-31 to 2027-12-31 estimated range: [6.73$, 12.66$]
Financial Metrics affecting the XERS estimates:
- Positive: with PPE of -1123.1 at the end of fiscal year the price was low
- Positive: 7.57 < Operating profit margin, % of 8.53
- Positive: -0.03 < Operating cash flow per share per price, % of 2.44
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of -0.06 > -0.60
- Negative: negative Industry operating income (median)
- Negative: -0.75 < Inventory ratio change, % of -0.13
- Negative: 0.74 < Interest expense per share per price, % of 2.48
Short-term XERS quotes
Long-term XERS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $163.91MM | $203.07MM | $291.85MM |
| Operating Expenses | $207.92MM | $236.72MM | $266.95MM |
| Operating Income | $-44.01MM | $-33.65MM | $24.90MM |
| Non-Operating Income | $-19.49MM | $-23.46MM | $-24.34MM |
| Interest Expense | $26.61MM | $30.48MM | $29.08MM |
| R&D Expense | $22.34MM | $25.56MM | $31.16MM |
| Income(Loss) | $-63.50MM | $-57.10MM | $0.55MM |
| Taxes | $-1.25MM | $-2.27MM | $0.00MM |
| Net Income(Loss)* | $-62.26MM | $-54.84MM | $0.55MM |
| Stockholders Equity | $-6.78MM | $-29.61MM | $13.69MM |
| Inventory | $38.84MM | $48.17MM | $68.67MM |
| Assets | $322.60MM | $323.06MM | $383.53MM |
| Operating Cash Flow | $-47.02MM | $-36.98MM | $28.63MM |
| Capital expenditure | $2.26MM | $0.87MM | $0.70MM |
| Investing Cash Flow | $-6.00MM | $4.88MM | $-0.70MM |
| Financing Cash Flow | $-1.61MM | $36.17MM | $11.39MM |
| Earnings Per Share** | $-0.45 | $-0.37 | $0.00 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.